CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney...
Phase 1
Columbus, Ohio, United States and 10 other locations
pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney...
Phase 2
Marion, Ohio, United States and 32 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Columbus, Ohio, United States and 280 other locations
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...
Phase 3
Columbus, Ohio, United States and 186 other locations
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this st...
Phase 2
Columbus, Ohio, United States and 52 other locations
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This...
Phase 3
Columbus, Ohio, United States and 591 other locations
The objective of this study is to establish that the MB-102 transdermal fluorescence-measured Glomerular Filtration Rate (GFR) using the MediBeacon®...
Phase 3
Columbus, Ohio, United States and 4 other locations
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients...
Phase 2
Columbus, Ohio, United States and 24 other locations
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in...
Columbus, Ohio, United States and 91 other locations
of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease...
Phase 3
Columbus, Ohio, United States and 292 other locations
Clinical trials
Research sites
Resources
Legal